| Date | Title | Description |
| 10.03.2026 | BioInnovation Institute adds 11 startups to Venture Lab cohort | BioInnovation Institute (BII), a Copenhagen-based non-profit innovation hub established by the Novo Nordisk Foundation, is supporting 11 companies through its 12-month Venture Lab programme. Each company receives €500,000 in convertible loa... |
| 03.03.2026 | BioInnovation Institute backs five startups with €1.3M in follow-on funding | BioInnovation Institute (BII), an initiative of the Novo Nordisk Foundation, has awarded an additional €1.3 million in follow-on funding to five portfolio startups, bringing total support per company to up to €1.8 million. The funding is in... |
| 17.02.2026 | To the shareholders of H. Lundbeck A/S | To the shareholders of H. Lundbeck A/S
Tue, Feb 17, 2026 10:00 CET Report this content NOTICE OF ANNUAL GENERAL MEETING
Notice is hereby given of the annual general meeting of H. Lundbeck A/S to be held on: WEDNESDAY, 18 MARCH 2026 AT 10:00... |
| 16.01.2026 | Novo Nordisk Foundation Fuels €736 Million European Innovation Drive | Novo Nordisk Foundation injects €736 million into BioInnovation Institute (BII), powering a decade-long drive to elevate European innovation. This landmark funding, spanning 2026-2035, targets a critical gap: translating world-class researc... |
| 15.01.2026 | Novo Nordisk Foundation backs BioInnovation Institute with €736M to scale life sciences and deeptech innovation | The Novo Nordisk Foundation has allocated up to €736 million (DKK 5.5 billion) to BioInnovation Institute (BII), a leading institute for life science and deep tech innovation in Copenhagen.
The funding will enable BII to expand its activiti... |
| 15.01.2026 | Novo Nordisk Foundation Commits €736 Million To BioInnovation Institute to Scale Innovation Across Denmark And Europe | The Novo Nordisk Foundation is allocating up to DKK 5.5 billion (about EUR 736 million) to Copenhagen-based BioInnovation Institute (BII) in a long-term funding framework running from 2026 through 2035, aiming to expand Denmark’s life scien... |
| 16.09.2025 | EQT Life Sciences portfolio company VarmX partners with CSL in a strategic collaboration and option agreement worth up to USD 2.2 billion | EQT Life Sciences portfolio company VarmX partners with CSL in a strategic collaboration and option agreement worth up to USD 2.2 billion
Tue, Sep 16, 2025 14:00 CET Report this content
VarmX is developing a bypass agent to restore coagulat... |
| 08.08.2025 | SNIPR BIOME Secures €35 Million to Revolutionize CRISPR-Medicine | Copenhagen's SNIPR BIOME clinched €35 million in Series B funding. This significant capital injection drives microbial CRISPR-medicine innovation. Funds target critical health challenges: developing CRISPR-Cas therapy for severe airway infe... |
| 08.08.2025 | Danish BioTech scale-up SNIPR Biome raises €35 million to target antimicrobial resistance in diseases like cancer | Copenhagen-based SNIPR Biome, a BioTech company innovating the development of microbial CRISPR-medicine, announced the close of a €35 million Series B raise to advance CRISPR-based therapies for cystic fibrosis airway infections, combat ant... |
| 07.08.2025 | SNIPR BIOME Raises EUR 35M in Series B Funding | SNIPR BIOME, a Copenhagen, Denmark-based company improving the development of microbial CRISPR-medicine, raised EUR 35M in Series B funding.
Backers included Cystic Fibrosis Foundation and the German Federal Agency for Breakthrough Innovati... |
| 23.06.2025 | Enterome: $19 Million Secured To Fund Development Of OncoMimics Immunotherapy To Treat Follicular Lymphoma | Enterome, a clinical-stage company developing first-in-class OncoMimics immunotherapies to treat cancer, announced that it has raised $19 million in new private financing to advance its lead clinical program, EO2463 OncoMimics immunotherapy... |
| 29.05.2025 | The Brain Prize: HM The King of Denmark presents prestigious prize to US and German scientists for seminal discoveries in brain cancer | Two pioneering scientists received The Brain Prize 2025 for their discoveries that open an entirely new way of thinking about and understanding brain cancers, and the potential strategies to treat them.
COPENHAGEN, Denmark, May 29, 2025 /PR... |
| 03.07.2024 | Quantum Computing Startup Kvantify Secures €10 Million to Revolutionize Life Science Sector | In a significant development, Copenhagen-based quantum software start-up, Kvantify, has successfully closed a €10 million seed round to propel the advancement of quantum computing in the life science sector. The funding, spearheaded by Dani... |
| 03.07.2024 | Copenhagen-based Kvantify secures €10 million to unlock quantum computing for the life science sector | Kvantify, a leading quantum software start-up, has announced the successful closure of a €10 million seed round. This funding will enable Kvantify to strengthen its position as a global leader in quantum computing, with an initial focus on ... |
| 03.07.2024 | Kvantify secures €10M Seed funding for quantum computing powered drug discovery | Danish Quantum software startup Kvantify, has announced the successful closure of a €10 million Seed round.
Kvantify leverages quantum and high-performance computing to create revolutionising solutions for complex scientific and industrial ... |
| 25.09.2023 | Notify Therapeutics secures €5M to develop novel hormone-free fertility treatment for women | Read this article in:
Copenhagen-based Notify Therapeutics, a “first-in-class” female fertility treatment, announced that it has secured €5M in a fresh round of funding.
Notify Therapeutics, an initiative stemming from Professor Karin Lykke... |
| 05.05.2021 | Cytoki Pharma cierra una ronda de €38M liderada por Lundbeckfonden Emerge junto con Ysios Capital, Seventure Partners y +ND Capital | 05/05/2021
Nota de prensa
YSIOS CAPITAL INVIERTE EN CYTOKI PHARMA.
− La compañía biotecnológica Cytoki Pharma (Copenhague, Dinamarca) desarrolla nuevas proteínas basadas en interleuquina 22 (IL-22) para el tratamiento de lesiones epiteli... |
| 05.05.2021 | Cytoki Pharma secures $45M Series A round lead by Lundbeckfonden Emerge together with Ysios, Seventure Partners and +ND Capital | 05/05/2021
Press release
CYTOKI PHARMA RAISES $45 MILLION SERIES A FINANCING.
Proceeds to support the development of its lead program (lipidated IL-22) through clinical proof of concept in Inflammatory Bowel Disease and explore expansion... |
| 09.07.2020 | VarmX raises €32M in Series B financing to develop innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants | 08/07/2020
Press release
VARMX RAISES €32 MILLION IN SERIES B FINANCING TO DEVELOP INNOVATIVE REVERSAL AGENT FOR THE TREATMENT AND PREVENTION OF SEVERE BLEEDING IN PATIENTS ON ORAL ANTICOAGULANTS.
• Financing co-led by Ysios Capital and ... |
| 08.07.2020 | Ysios Capital lidera una inversión de €32M en VarmX | 08/08/2020
Nota de prensa
YSIOS LIDERA UNA INVERSIÓN DE €32 MILLONES EN VARMX.
– VarmX (Leiden,Países Bajos), está desarrollando un fármaco innovador para el tratamiento y prevención de hemorragias graves en pacientes tratados con antico... |
| 02.04.2019 | Aura Biosciences cierra una ronda Serie D de $40M liderada por Medicxi, acuden Ysios, Advent Life, Aris Bioscience, Chiesi, ColumbusVP y Lundbeckfonden | 02/04/2019
Nota de prensa
AURA BIOSCIENCES CIERRA UNA RONDA SERIE D DE $40 MILLONES LIDERADA POR MEDICXI, ACUDEN YSIOS CAPITAL, ADVENT LIFE SCIENCES, ARIS BIOSCIENCE, CHIESI, COLUMBUSVP Y LUNDBECKFONDEN.
Aura Biosciences, a leader in the... |
| 03.04.2017 | Cydan Development Announces the Acquisition of Its First Rare Disease Spin-out, Vtesse, Inc. by Sucampo Pharmaceuticals, Inc. | Link to Release
Cambridge, Mass., April 3, 2017 – Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improve the lives of people living with rare genetic diseases, today announces that Vtesse, Inc., ... |
| 08.09.2015 | Sanifit cierra una ronda de €36,6M liderada por Ysios. Acuden Caixa CR, Lundbeck fonden, Forbion, Gilde, Edmond Rothschild y Baxter | 08/09/2015
SANIFIT CIERRA UNA RONDA DE €36,6 MILLONES LIDERADA POR YSIOS. ACUDEN CAIXA CAPITAL RISC, Y LOS INTERNACIONALES LUNDBECK FONDEN, FORBION, GILDE, EDMON DE ROTHSCHILD Y BAXTER.
La empresa biofarmacéutica Laboratoris Sanifit S.L.,... |
